Open Orphan wins €4m contract to conduct trial for new RSV treatment
Dublin-listed pharmaceutical services company says contract is with top three pharma group
Open Orphan is also working on an antibody testing service that will have capacity for up to 3,000 tests per day. Photograph: Nicolas Asfouri/AFP
Dublin-listed pharmaceutical services company Open Orphan has secured a €4 million contract to trial a new treatment for respiratory syncytial virus (RSV), which causes infections of the lungs and respiratory tract.
The study commissioned by a leading pharma group will take place at Open Orphan subsidiary hVivo’s quarantine facility in Whitechapel, London and is expected to be completed by the end of quarter one 2021.